SONN

Sonnet

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 3

Sell signal 3

consensus rating "Strong Buy"

ample liquidity

High Gross Profit Margin

Revenue Plunges

Net Income Plunges

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About SONN

Sonnet Biotherapeutics Holdings, Inc.

A biopharmaceutical company that develops innovative targeted biologic drugs

Industry

Biological Technology

Established Date

10/21/1999

Listing Date

06/21/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

09-30

Website

www.sonnetbio.com

Security Type

Common stock

Office address

100 Overlook Center, Suite 102, Princeton, NJ 08540

Business

Introduction

Sonnet BioTherapeutics Holdings, Inc., was incorporated under the laws of the State of Delaware on October 21, 1999. The company is a clinical biopharmaceutical company with a patented technology for the development of novel biopharmaceuticals called FHAB (Complete Human Albumin Binding). FHAB utilizes a fully human single-chain antibody fragment (scFv), linked to one or two therapeutic molecules, capable of affecting a single or bispecific mechanism of action. The FHAB structure contains a domain designed to bind to human serum albumin (HSA) and "free ride" for transport to targets such as solid tumors or the lymphatic system. The company designed the structure to promote the accumulation of the drug in specific tissues and prolong the duration of activity in the body. FHAB development candidate cells are produced in mammalian cell culture to glycosylate, thereby reducing the risk of immunogenicity. The company's FHAB technology is well suited for future drug development in the field of human diseases, including oncology, autoimmune, pathogenic, inflammatory and hematological diseases.

Company Financials

EPS

SONN has released its 2025 Q1 earnings. EPS was reported at -1.56, versus the expected -11.12, beating expectations. The chart below visualizes how SONN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SONN has released its 2025 Q1 earnings report, with revenue of 1.00M, reflecting a YoY change of 5268.84%, and net profit of -3.16M, showing a YoY change of -170.49%. The Sankey diagram below clearly presents SONN’s revenue sources and cost distribution.